Moreover, our research did not extend to evaluating the risk of lower limb complications associated with SGLT2 inhibitors in non-diabetic populations, such as individuals with heart failure or chronic kidney disease who do not exhibit diabetic symptoms. This evidence concerns the gene SLC5A2 and chronic kidney disease.